Thermo Fisher Scientific Sees Huge Stake Increase by Broyhill Asset Management

Broyhill Asset Management boosts its position in the medical research company by 530% in Q3 2025.

Mar. 14, 2026 at 7:35am

Got story updates? Submit your updates here. ›

Broyhill Asset Management LLC significantly increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the third quarter of 2025, according to a recent 13F filing. The firm now owns 7,024 shares of the medical research company's stock, making it Thermo Fisher's 10th largest holding and accounting for approximately 3% of Broyhill's total portfolio.

Why it matters

Thermo Fisher Scientific is a major player in the medical research and instrumentation industry, providing critical tools and services to laboratories and manufacturers worldwide. Broyhill's substantial investment in the company signals their belief in Thermo Fisher's long-term growth potential, even as the stock has faced some volatility in recent quarters.

The details

According to the 13F filing, Broyhill Asset Management increased its position in Thermo Fisher Scientific by 530% during Q3 2025, adding 5,909 shares to its existing stake. The firm now owns a total of 7,024 shares valued at $3.4 million, making Thermo Fisher its 10th largest holding. This represents a significant boost in Broyhill's conviction around Thermo Fisher's business and future prospects.

  • Broyhill Asset Management increased its Thermo Fisher Scientific stake during the 3rd quarter of 2025.

The players

Broyhill Asset Management LLC

An investment management firm that has significantly increased its stake in Thermo Fisher Scientific, making it one of the company's top 10 institutional shareholders.

Thermo Fisher Scientific Inc.

A global provider of scientific instrumentation, reagents, software, and services that support research, clinical, and industrial laboratories.

Got photos? Submit your photos here. ›

The takeaway

Broyhill Asset Management's substantial investment in Thermo Fisher Scientific underscores the medical research company's strong market position and growth potential, even as the broader stock faces some near-term volatility. This development highlights the continued appeal of Thermo Fisher's diversified portfolio of essential scientific tools and services.